The present invention relates to a long-acting sustained-release dosageform for treatment of Parkinson Disease, comprising a dopamine receptoragonist and a pharmaceutically acceptable biodegradable polymer accessories,wherein the content of the dopamine receptor agonist in the sustained-releasedosage form is 5-50% by weight, and the content of the pharmaceuticallyacceptable polymer accessories is 50-95% by weight.